Related Experiment Video
Updated: May 16, 2026

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
Published on: September 14, 2019
[Challenge toward gene-therapy using iPS cells for Duchenne muscular dystrophy]
Mitsuo Oshimura1, Yasuhiro Kazuki, Narumi Uno
1Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Science, Tottori University.
Human artificial chromosomes (HACs) carrying the dystrophin gene successfully corrected genetic deficiencies in Duchenne muscular dystrophy (DMD) models. Engineered cells, including iPS cells and mesoangioblasts, showed dystrophin expression and potential for regenerative therapy.
Area of Science:
- Genetics
- Stem Cell Biology
- Regenerative Medicine
Context:
- Duchenne muscular dystrophy (DMD) is a severe genetic disorder.
- Human artificial chromosomes (HACs) are episomal vectors for large gene delivery.
- Mesoangioblasts are stem cells with potential for muscle regeneration.
Purpose:
- To assess the efficacy of DYS-HAC transfer for correcting genetic defects in DMD.
- To evaluate the therapeutic potential of engineered iPS cells and mesoangioblasts for DMD.
- To explore autologous cell therapy strategies for DMD.
Summary:
- Human artificial chromosomes (HACs) containing the dystrophin gene (DYS-HAC) were transferred into induced pluripotent stem (iPS) cells from DMD models and patients.
- Engineered iPS cells and mesoangioblasts demonstrated dystrophin expression in vitro and in vivo, with functional correction observed in DMD model mice.
- Successful differentiation of corrected iPS cells into mesoangioblasts suggests a viable autologous cell therapy approach for DMD.
Impact:
- This research demonstrates the potential of HACs for gene correction in genetic disorders like DMD.
- Engineered stem and progenitor cells offer promising avenues for regenerative medicine and personalized therapies.
- Autologous cell transplantation could circumvent immune rejection, enhancing therapeutic safety and efficacy for DMD patients.
More Related Videos
10:28Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
Published on: April 3, 2021
09:11Generation of Induced Pluripotent Stem Cells from Muscular Dystrophy Patients: Efficient Integration-free Reprogramming of Urine Derived Cells
Published on: January 28, 2015
Related Concept Videos
Gene Therapy
Gene Therapy
iPS Cell Differentiation
Satellite Stem Cells and Muscular Dystrophy
EPS and iPS Cells in Disease Research
Somatic to iPS Cell Reprogramming